drug - induced dermatological reactions are common with the antiepiletic drugs such as carbamazepine ( cbz ) , phenytoin , lamotrigine , ethosuximide , and phenobarbital .
these reactions may occur in the mild form as benign rash or may be severe and life - threatening as erythema multiforme major or toxic epidermal necrolysis ( ten ) .
erythema multiforme major , also known as stevens - johnson syndrome , is usually caused by reactions to medications , rather than infections .
cbz was originally introduced in therapeutic armamentarium as an anticonvulsant , and is known to produce such adverse drug reaction ( adr ) , but the reports are rare .
cbz is still used as a first - line agent along with lithium and valproic acid in the treatment of bipolar disorder .
although there are case reports of stevens johnson syndrome ( sjs ) occurring in schizophrenia , bipolar affective disorder , and during a manic episode when treated with cbz , we were unable to find reports of sjs in patients having epilepsy with bipolar affective disorder .
sjs is a blistering disorder , characterized by mucosal erosions at two or more sites with small blisters and purpuric macules .
a 17-year - old woman was brought to psychiatry opd with complaints of episodes of decreased sleep , irritability , and occasional aggressive and violent behavior .
she was already on sodium valproate 600 mg / day for generalized tonic - clonic seizures , since the last 2 years from a primary health centre of uttarakhand state .
she had a history of 510 convulsions per day for 23 days and then seizure free period of 1015 days .
she accepted noncompliance to the regular treatment , thrice for 1520 days duration each , during the last 2 years , and admitted that a further increase in seizure frequency during such breaks compelled her to resume the treatment subsequently . on examination ,
she had history of frequent mood swings of mania and depression associated with episodic behavioral changes which was undoubtedly suggestive of bipolar affective disorder .
she was diagnosed as a case of bipolar affective disorder , currently in remission , with comorbid epilepsy .
the patient was initiated on higher dose ( 800 mg ) of sodium valproate which was further increased gradually to 1600 mg / day . at this stage ,
a further increase in dose caused significant sedation and was intolerable . at this stage , she was referred to a neurologist which she refused to comply with .
cbz 200 mg once daily was added to her regimen of valproate 1600 mg / day in consultation with the hospital physician , which was increased to twice daily after 5 days and then three times daily after 10 days of initiation .
she tolerated the treatment well until 19 day when she returned with high - grade fever , redness of eyes , swelling all over body , eruptions on lips , face in butterfly pattern [ figure 1 , 2 ] and was admitted in the dermatology ward . on examination
her axillary temperature was 39c , blood pressure was 90/60 mmhg , and the pulse rate was 70 per min and regular .
she had multiple bullae formation all over the body in the symmetrical pattern which gradually increased to involve > 6065% of the body surface area .
she had severe pain during deglutition , generalized body edema , and bleeding per vagina .
examination by a gynecologist revealed that she was in the menstruating phase and vaginal mucosa was found ulcerated .
lesions on patient 's face in the butterfly pattern lesions on patient 's trunk her lab investigations showed that heamogloblin was 13 g/ dl , total leukocyte count 6000/mm , platelets 1.5 lakhs / mm , creatinine 0.9 mg / dl , urea 49 mg / dl , sodium 139 meq / l , and potassium 4.8 meq / l .
examination of urine revealed albumin ( + ) and full field rbcs , which correlated with her menstruation phase .
biopsy was not done as her clinical presentation was compatible with diagnosis of erythema multiforme major which was confirmed with an opinion from the pharmacologist .
she was treated with methylprednisolone , chlorpheniramine , and ceftriaxone parenterally , and clobetasol  gentamicin combination topically , along with iv fluids and other supportive measures .
after about 2 weeks of intensive indoor management , her conditions started improving and during third week she was again put on oral valproate 200 mg with an incremental increase of 200 mg per day till it reached 1600 mg / day on eighth day of initiation .
the patient again started feeling drowsy , which may have had a psychological component as the patient was already anticipating the effect due to past experience .
she refused any other addition to her treatment for fear of similar reaction and agreed to bear the possibility of few convulsions per month .
two months after discharge , the patient returned for review and the dose of sodium valproate was increased since the sedation was tolerable .
her dose was increased to 1800 mg and then to 2000 mg in the next month . with this dose
she started having about 34 months of seizure free period and maintained on the same dose since the last 6 months .
cutaneous lesions mostly occur on the palms , soles , dorsum of the hands , and extensor surfaces .
mucosal involvement may include erythema , edema , sloughing , blistering , ulceration , and necrosis .
this patient had been taking valproate for 2 years , and her investigations were not suggestive of any other etiology for causation of these adrs .
cutaneous reactions started within 3 weeks of administration of cbz , which is the usual risk period for this adr .
the causality assessment by naranjo 's algorithm was done which revealed a score 7 suggesting a probable adr to cbz .
in one such a report , a 6-year - old boy developed sjs five weeks after cbz was added to valproic acid , which he had been taking as sole antiepileptic therapy for several weeks .
another study showed the incidence of skin rashes with the same dose of cbz in psychiatric patients ( 1215% ) was nearly three times more than that in neurological patients ( 5% ) .
however , no study showing incidence in comorbid neurological and psychiatric patients was found during our search , hence we lack any comparison with our case report .
our patient also received sodium valproate which is also known to cause hypersensitivity reactions , but the patient had been taking valproate since the last 2 years without any adrs .
it was only after the administration of cbz along with a higher dose of valproic acid that this patient developed severe adrs .
immunological reactions due to hormonal changes during menstruation trigger various hypersensitivity reactions such as mucosal ulcerations , skin rashes , asthma , etc .
, so it may be an important factor in drug reactions which is yet an unreported factor and should be considered in further studies .
approximately three persons per million per week may experience life - threatening dermatological syndromes with the use of cbz .
the incidence of adrs may increase when cbz is given along with higher doses of valproic acid because of increased plasma concentrations of cbz .
this was a rare case of life - threatening erythema multiforme major / stevens johnson 's syndrome with the use of cbz when given along with higher doses of valproic acid .
it was perceived that menstruation , and comorbidity of neurological and psychiatric illnesses might have had predisposing roles .
there is a need of continued adr monitoring and reporting of adrs , more so with the use of cbz .
 carbamazepine ( cbz ) is frequently used for epilepsy and various psychiatric illnesses . 
 it is known for its dermatological side effects which may range from mild rash to life - threatening reactions as stevens johnson syndrome or toxic epidermal necrolysis . 
 we hereby report a rare case of 17-year - old woman suffering from generalized tonic clonic epilepsy with comorbid bipolar affective disorder , who was initially treated with sodium valproate with partial improvement . 
 after 19 days of addition of cbz to the therapy , the patient developed erythema multiforme major with > 60% skin involvement and oral , conjunctival , intestinal , and vaginal mucosal involvement . 